SMAD1 and osteoporosis: Runx1 maintained adult bone homeostasis and bone differentiation though upregulating Bmp7/Alk3/Smad1/5/8/Runx2/ATF4 and WNT/β-Catenin signaling pathways, suggesting that targeting Runx1 might be a novel therapeutics for osteoporosis [11].